5244702026-04-012026-06-305244702026-06-305244702026-04-012026-06-30in-capmkt:OtherExpenses1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524470SYNCOMFNOTLISTEDINE312C01025SYNCOM FORMULATIONS INDIA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-112026-08-06INRLakhsQuarterlyFirst quarterMulti segment2026-08-1116:00:002026-08-1116:45:00Not applicable2026-04-012026-06-30UnauditedConsolidated1255264000782940001333558000587762000182449000-11157200017166700024450001540300016288200010110360003225220000322522000727650001289000740540000248468000000024846800038187000286655000000094000000010.260.26000.260.26Others162882000Pharmaceuticals Drugs & formulations1322361000Trading of Commodities2784000Renting of Property8413000133355800001333558000Pharmaceuticals Drugs & formulations317025000Trading of Commodities199000Renting of Property774300032496700024450000322522000Pharmaceuticals Drugs & formulations4603715000Trading of Commodities456000Renting of Property925724000552989500005529895000Pharmaceuticals Drugs & formulations1078914000Trading of Commodities1250000Renting of Property28416000110858000001108580000 <br /> 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11.08.2026 <br /> 2 These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. <br /> 3 The company is operating in 3 segments i.e. a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property, particulars of segment wise results are given as required. <br /> 4 As required under Regulation 33 of SEBI LODR Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2026. The report does not have any impact on the above results and notes which needs explanation. <br /> 5 The Company currently have 3 Three Wholly owned Subsidiaries namely Synmex Pharma Pvt Ltd , Vincit Pharma Pvt Limited and Sante Biotech Pvt Ltd <br /> 6 During the current period, the Company has corrected its method of calculating Earnings Per Share EPS. In previous years/Quarters, EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33, the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently, the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previously reported and restated are as below <br /> Previously Reported EPS TCI Quarter Ended Year Ended <br /> 30-06-2026 31-03-2026 30-06-2025 31-03-2026 <br /> Unaudited Audited Unaudited Audited <br /> Earnings per equity share for discontinued & continuing operations <br /> (1) Basic NA NA 0.21 NA <br /> (2) Diluted NA NA 0.21 NA <br /> Restated EPS PAT <br /> Earnings per equity share for discontinued & continuing operations <br /> (1) Basic 0.26 0.27 0.17 0.81 <br /> (2) Diluted 0.26 0.27 0.17 0.81 <br /> 0Item that will be reclassified to profit and loss3818700038187000038187000